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Abstract
Background: Newborn hearing screening has to be considered the first step of a program for the identification,
diagnosis, treatment and habilitation/rehabilitation of children with hearing impairment.
Main Part: In Tuscany Region of Italy, the universal newborn hearing screening is mandatory since november 2007.
The first guidelines for the execution of the screening have been released in June 2008; then many other Italian regions
partially or totally adopted these guidelines. On the basis of the experience from 2008 and according to the recent
evidences in the scientific literature, a new screening protocol was released in Tuscany region. The new protocol is an
evolution of the previous one. Some issues reported in the previous protocol and in the Joint Committee on
Infant Hearing statement published in 2007 were revised, such as the risk factors for auditory neuropathy and for
late onset, progressive or acquired hearing loss. The new updated guidelines were submitted to the Sanitary
Regional Council and then they have been approved in August 2016. The updated screening protocol is mainly
aimed to identify newborns with a congenital moderate-to-profound hearing loss, but it also provides indications
for the audiological follow-up of children with risk’s factor for progressive or late onset hearing loss; further it
provides indications for the audiological surveillance of children at risk for acquired hearing impairment. Then, in
the new guidelines the role of the family paediatrician in the newborn hearing screening and audiological
follow-up and surveillance is underscored. Finally the new guidelines provide indications for the treatment with
hearing aids and cochlear implant, in accordance with the recent Italian Health Technology Assessment (HTA)
guidelines.
Conclusions: In the paper we report the modality of execution of the universal newborn hearing screening in the
Tuscany Region, according to the recently updated protocol. The main features of the protocol and the critical issues
are discussed.
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Background
The universal newborn hearing screening (NHS) is aimed
to identify babies with moderate to profound hearing im-
pairment present at birth (unilateral or bilateral) [1, 2].
NHS has to be considered as a first step of a pro-
gram for the identification, diagnosis, treatment and
habilitation/rehabilitation of children with hearing im-
pairment [1].
Tuscany is a region in central Italy with an area of
about 23,000 km2 and a population of about 3.8 million
inhabitants (2016).
Totally, there are 26 childbirth points in Tuscany: 25
are public structures and 1 is in a private clinic. In 2015
488.000 babies were born in Italy, of which 27.500 in
Tuscany (5,64%).
In Tuscany Region of Italy, the first guidelines for the
execution of the Universal Newborn Hearing Screening
(UNHS) have been released in June 2008; then many
other Italian regions partially or totally adopted these
guidelines. Furthermore, in the 2017 “essential health
care levels” (livelli essenziali di assistenza, LEA, in Italian
language) document, the NHS is reported to be
mandatory for each Italian region.
In 2011 a report by the Regional Agency for Health on
NHS execution in Tuscany attested that 100% of the
Tuscanian childbirth clinics executed the UNHS and
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that more than 98% of the neonates born in Tuscany
underwent the procedure [2].
On the basis of the experience from 2008 and accord-
ing to the recent evidences in the scientific literature, a
new screening protocol was released in Tuscany region.
The new protocol was based on the previous one and on
the Joint Committee on Infant Hearing (JCIH) statement
published in October 2007. In the JCIH statement, in-
deed, there is a list of all auditory risk factors marked
with different symbols, in order to point out the indica-
tors associated with an higher risk (e.g. received extra-
corporeal membrane oxygenation or positivity for CMV
infection). All infants with indicator for hearing loss are
reported to be referred for an audiological assessment at
least once by 24–30 months of age; children with risk
factors associated with an higher risk for delayed-onset
hearing loss have to substain more frequent audiological
assessments [1]. These aspects were revised and modi-
fied and the new updated guidelines were submitted to
the Sanitary Regional Council and then they have been
approved in August 2016.
The updated screening protocol is mainly aimed to
identify newborns with a congenital unilateral or bilat-
eral, moderate-to-profound hearing loss, but it is also
provides indications for the audiological follow-up of
children with risk’s factor for progressive or late onset
hearing loss; further it provides indications for the
audiological surveillance of children at risk for acquired
hearing impairment. Then, in the new guidelines we
underlined the role of the family paediatrician in the
newborn hearing screening and audiological follow-up
and surveillance.
Finally the new guidelines provide indications for the
treatment with hearing aids (HA) and cochlear implant
(CI), in accordance with the recent Italian Health Tech-
nology Assessment (HTA) guidelines [3].
In the following sessions we report the modality of
execution of the UNHS in the Tuscany Region in Italy,
according to the recently updated protocol.
Methods
In Tuscany, the centres that are involved in the NHS and
in the early diagnosis and treatment of hearing impair-
ment in childhood are divided in 3 levels, depending on
facilities and personnel available in the childbirth and in
the audiologic clinic. The modalities of screening execu-
tion are adjusted on the bases of each centre’s resources.
Level I centre
– the childbirth unit has the last generation’s facilities
for measurement of Transient Evoked Oto-Acoustic
Emissions (TEOAE) only. The test is executed by the
paediatrics nurse, paediatrician, and/or the
audiometrist, audiologist or ENT specialist, after an
appropriate training.
Level II centre
– the childbirth unit has the last generation’s facilities
for measurement of TEOAE and the equipment for
automatic auditory brainstem responses (AABR) or
clinical auditory brainstem responses (ABR). The
test is executed by the audiometrist, the audiologist
or, eventually, from the ENT specialist, the
paediatrician, the paediatrics nurse, after an
appropriate training.
Level III centre
– the structure has the last generation facilities for
TEOAE and AABR in childbirth clinic; further the
structure is provided with an audiological ward
including the equipment for clinical ABR with
threshold definition, clinical TEOAE, Distortion
Produced Oto-Acoustic Emissions (DPOAE), imped-
ance audiometry and behavioural audiometry; fur-
thermore the structure has experienced personnel in
the early diagnosis of hearing loss, in the rehabilita-
tion of children with HA or CI, and it has a suitable
arrangement for the execution of aetiological investi-
gations (infectious disease specialist, geneticists, neu-
roradiologists, ex.)
The screening procedure should be always executed
within the discharge of the baby from the childbirth unit,
except for few complex situations (e.g. newborn voluntary
early discharge). In those situations an appointment for
the screening procedures is given at the discharge, accord-
ing to the audiological centre’s personnel. The childbirth
centre repeats the test within 2 weeks from the birth of
the babies for verify the refer cases; a dedicated structure
for collect babies with refer results can be arranged.
In the paper published by our group in 2011 the 1,04%
of neonates born in the Neonatal Unit of Santa Chiara
Hospital in Pisa, underwent a further audiologic assess-
ment after been defined as refer at NHS. In the 0,42% of
all the children underwent the NHS, has been made a
final diagnosis of hearing impairment [2].
Each hospital must identify for each childbirth unit a
person in charge of screening’s procedures and data-
bases; this professional would be a paediatrician or an-
other specialist (audiologist and/or ENT specialist), and
he/she would involve nurses and/or audiometrists in the
execution of the screening’s tests.
We suggest that each childbirth centre selects qualified
personnel for the execution of the tests (paediatrician,
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audiometrist, paediatrics nurse, audiologist, ENT special-
ist). Generic operators has to be avoided.
All the childbirth centres with an high number of
births per year, the centres with a neonatal intensive
care unit (NICU), the II and the III level centres
should have a continuous connection with the Audi-
ology/ENT unit and dedicated audiomestrists. Further,
specific training courses can be arranged for the oper-
ators in each local area.
The access at screening’s procedure for children born in
private hospitals in Tuscany region has been established,
as well as the procedures for children born at home.
Furthermore, babies born in other Italian regions or
abroad and adopted children that did not attend the
screening procedures, must undergo hearing screening
(or other audiologic tests adequate for the age of the
subject) in the audiologic centre, within one month from
the birth or from the taken in charge from the
paediatrician.
Is it necessary to differentiate the execution’s modality
of the UNHS in newborns with or without risk’s factors
for auditory neuropathy (AN). In Table 1 we report risk’s
factors for AN.
Screening on newborns without risk’s factors for auditory
neuropathy (Fig. 1)
TEOAE in childbirth centres are measured by the re-
sponsible personnel within the discharge of the baby
from the childbirth unit generally after 24 h of life.
The TEOAE should be measured during the spontan-
eous sleep of the baby after the nutrition, possibly in
silence. If the TEOAEs are present (pass) on both
ears the procedure is concluded. If in one or both the
ears no TEOAEs (refer) are measured, another meas-
urement in both ears [1] is repeated after some
hours, but within the discharge of the baby. If the
TEOAE are bilaterally present at the second measure-
ment (pass), the procedure is concluded. If TEOAEs
are absent in one or both ears and if personnel and
facilities are disposable for the measurement of AABR
(level II centre), an AABR measurement is done
within the discharge of the baby from the childbirth
unit; if AABR are normal (pass) the procedure is con-
cluded. In fact, AABR (with stimulus level set at
45 dB HL) has got an high specificity, providing a
very small number of false positive cases. TEAOEs,
indeed, is a test more sensible then the AABR, but it
can present an higher number of false positive cases.
For that reason we decided to consider pass at
screening a newborn with pass AABR and refer
TEAOEs, but we also considered necessary that those
babies has to be closely followed by the paediatrician.
In newborns resulted refer at screening procedures
with TEAOE that have not executed AABR before the
discharge, a repetition of TEAOE in both ears within 7–
15 days is suggested.
Cases that still result refer at second TEOAE measure-
ment are addressed to II or III level centres for the II
level screening’s procedure with the execution of ABR
(automatics or clinical) within a month from the birth.
Babies resulted refer at II level screening’s procedure
(TEOAE + AABR) are addressed within III month from
the birth, to III level centres for a diagnostic-audiologic
complete assessment (clinical ABR with threshold evalu-
ation, impedance audiometry, stapedial reflexes +
TEOAE, ex.). Then, further diagnostic sessions, hearing
aids fitting and rehabilitation procedures can be per-
formed, and within the 6th month from the birth of the
baby a therapeutic and rehabilitative treatment has to be
assessed. In newborns with severe-profound bilateral
hearing loss, an as-early-as-possible (3rd - 4th month)
hearing aids fitting and speech therapy is desirable to re-
duce as much as possible the time of hearing
deprivation.
All the newborns resulted refer at I level screening
with TEOAE must be submitted to CMV DNA re-
search in urine by PCR within the 15th day from the
birth.
At the discharge from the childbirth centre, the person
in charge of the screening procedure or its collaborators
must:
1. report UNHS results on baby’s paediatrics booklet
2. report on the register of childbirth centre the result,
the execution’s modalities of the screening and the
category of the baby: with or without risk’s factors
for auditory neuropathy, with or without risk’s
factors for progressive or late onset hearing
impairment
3. report the screening’s result in an online secured
database
4. inform the parents and the paediatrician of hearing
screening’s results. Further, if the baby result refer
UNHS, the childbirth centre’s personnel must
inform to the parents, verbally and with an
informative paper about the instruction for the II
level evaluative tests
5. having previously contacted the responsible
audiologic centre, the personnel must inform the
Table 1 Risk factors for AN
1. Hospitalization in NICU for more than 5 days
2. Positive familiar anamnesis for infantile permanent hearing
impairment
3. Positive familiar anamnesis for neurodegenerative disorders,
as Hunter syndrome, sensitive-motor neuropathies, Friedreich’s
atassia, Chacot-Marie-Thoot syndrome.
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parents about the appointment for the II or III level
evaluative tests (an informatics booking system
between the audiologic centre and the childbirths
centre is suggested)
6. the II level evaluative tests have to be executed
within a month from the discharge from the
childbirth centre and the audiological diagnosis has
to be accomplished within 3 months from the
discharge from the childbirth centre
The booking system and the database permit to re-
duce lost to follow-up cases. In fact for each newborn
resulted refer at NHS, a new retest in the audiologic
centre is scheduled before the discharge. Further the
responsible personnel constantly check the database,
verifying that all the refer cases execute the audiologic
evaluation.
Screening on newborns with risk’s factors for auditory
neuropathy (Fig. 2)
A distinction between the execution of screening protocol
in newborns with and without risk’s factors for auditory
neuropathy is needed. So, newborns with the characteristics
reported in Table 1 must undergo the screening both with
TEOAE and AABR, in order to identify possible cases of
auditory neuropathy. It is well known that AN has an
higher incidence in the categories of babies reported in
Table 1 and it is not identified with TEOAE (that may re-
sults present in those patients).
All the newborns that show the condition reported in
Table 1 must undergo a specific diagnostic protocol.
If the newborn is preterm, the screening’s procedure
has to be executed at the end of the 35th gestational
week or after, but within the discharge, in order to re-
duce the incidence of false positive; before the 35th
week, indeed, the execution of TEOAE may be difficult
for the limited dimensions of the external auditory canal
and the AABR’s responses may be not revealed for an
immaturity of the central hearing pathways.
Babies belonging at the categories reported in Table 1
have to execute the TEAOE and AABR measurement be-
fore the discharge from the childbirth centre or within a
month (II level centres). If the result is refer, is suggested
to execute the tests at least 2 times before the discharge.
For this procedure is strongly suggested a collaboration
with skilled personnel (in particularly with audiometrist).
Fig. 1 Universal neonatal hearing screening for newborns without risk factors. Legend: flowchart for the neonatal hearing screening in newborns
without risk factors for auditory neuropathy
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Newborns resulted refer at TEOAE must execute,
within the 15th day from the birth, the research of CMV
DNA by PCR in urine.
Babies resulted refer for one or both ears are addressed
to the III level centre for an audiological evaluation.
At the discharge, the responsible personnel for the screen-
ing procedure or its collaborators must follow the guidelines
reported in the previous paragraph at point 1, 2, 3, 4, 5, 6.
Babies included in risk categories that was born in I
level centre, must undergo AABR in II or III level centre
to complete the screening’s procedure within a month
from the birth.
Surveillance on children with risk for progressive or late-
onset hearing loss
Children with risk’s factor for progressive or late-onset
hearing loss (Table 2) have to undergo an audiologic as-
sessment in a III level centre, once every 6–12 months
since the 3rd year of age and then once every year since
the 6th year of age:
The personnel in charge of screening’s protocol have
to inform the paediatricians about the inclusion of ba-
bies in the group of patients at risk for progressive or
late-onset hearing loss, during the discharge of the baby
from the childbirth centre.
Surveillance on children with risk for acquired hearing loss
Children that acquire post-natal infections associated
with sensorineural hearing loss (e.g. bacterical meningi-
tis) or suffer for cranial trauma (with loss of conscious-
ness and/or cranial fractures) or sustain chemotherapy
(e.g. with cisplatinum) or treatments with ototossic
drugs (e.g. aminoglicosidis), have to undergo an audio-
logical evaluation. Further, an audiologic assessment has
to be executed in every cases in which the family or the
Fig. 2 Universal neonatal hearing screening for newborns with risk factors. Legend: flowchart for the neonatal hearing screening in newborns
with risk factors for auditory neuropathy
Table 2 Risk factors for progressive or late-onset hearing loss
1. Positive familiar history for infantile hearing loss
2. Intrauterine CMV or rubella infections
3. Syndromes associated with late-onset or progressive hearing
loss (Pendred Syndrome, distal renal tubular acidosis (dRTA),
Waardenburg syndrome type II, brachio-oto-renal syndrome (BOR),
Usher syndrome, Stickler syndrome, CHARGE syndrome, Down
syndrome, Turner syndrome, Alport syndrome, exc.
4. Neurodegenerative disorders, such as Hunter syndrome or
sensorimotor neuropathies, such as Friedreich atassia or
Charcot-Marie-Tooth syndrome
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educators suspect an hearing impairment or in every
case of a delay in speech development (Table 3).
Further all the newborns admitted to an hospital dur-
ing the first months of life, in whom occur hyperbilirubi-
nemia that require exanguino-transfusion, sepsis with
positive coultural examination, bacterial meningitis,
since those conditions are risk’s factors for hearing loss,
must undergo a new screening with TEOAE and AABR
within the discharge.
Role of the family paediatrician
The paediatrician has a key role in the supervision of the
execution of screening’s procedure, in the execution of
an audiologic follow-up and in the surveillance of chil-
dren at risk of progressive or late-onset hearing loss (see
Table 2); further, paediatricians have to identify the chil-
dren with risk’s factors for acquired hearing impairment
(see Table 3).
The paediatrician has also to verify the correct execu-
tion of the screening; and it has to forward children born
abroad or in regions in which UNHS is not executed to
the responsible audiologic centre; it has to supervise the
newborns resulted refer at UNHS till the II level retest
and oversee on the children with risk’s factors for pro-
gressive or late-onset hearing loss, including babies with
refer result at TEOAE and pass at AABR, or those with
risk’s factor for acquired hearing loss. The paediatrician,
then, must verify that the CMV research in urine with
PCR has been executed in all the babies resulted refer at
screening with TEOAE measurement (see Figs. 1 and 2).
Finally, in case of children resulted refer at screening’s
protocol, the general paediatrician has to verify that the
audiological evaluation and diagnosis is carried out in
the proper time (within 3 months from birth).Moreover
in the new protocol for UNHS in Tuscany region is sug-
gested that the paediatrician execute a constant audio-
logical surveillance with specifically developed surveys.
These surveys have been developed with the collabor-
ation of the family paediatricians of the Tuscany region
and are aimed to identify red flags of hearing loss. Beside
having a key role in identifying cases with acquired, pro-
gressive or late-onset hearing loss, the family
pediatrician has a key role in the identification of false
negative cases (Table 4).
Discussion
UNHS represents the only way to identify children with
a congenital moderate-to-profound hearing loss. Thanks
to advances in technology both in TEOAE and AABR
measurements, UNHS became a very accurate proced-
ure. Relaying on the last generation technologies and on
specifically trained personnel, the sensitivity and the spe-
cificity of NHS programmes are very high. To date
homogeneous data on the sensitivity of UNHS programs
are not available, while the reported specificity is about
97–98%.
Measuring both TEOAE and AABR false positive cases
are strongly decreased. The possibility of false negative,
indeed, is a critical issue since it may lead to a delayed
diagnosis of hearing impairment, with consequences on
rehabilitation results in terms of hearing abilities and
linguistic and communicative skills [4].
After the audiologic assessment of refer newborns, the
person in charge of the screening procedure should be
informed about the audiological diagnosis.
Children with progressive or late-onset hearing loss
are not identified by the UNHS tests; the chance to
identify them is represented by the programs of long
term audiological follow-up and surveillance. Progressive
or late onset hearing loss may be related to many causes
(genetic predisposition, infections, drugs, exc.) and they
represent a large proportion of hearing impairment in
children (20–30%), even if reliable international data on
the subject are not available [5, 6].
In the same way, babies with acquired hearing loss
(e.g. due to bacterial meningitis) are not identified by the
screening, and those cases can be precociously identified
by the audiological surveillance’s programs [5, 6].
The JCIH in 2007 Position Statement, identified the
problems related with progressive, late-onset and ac-
quired hearing loss, and it defined the risk’s factors in
which is recommended an audiologic follow-up in the
first years after the birth [1]. The classification of risk’s
factors reported in the JCIH Position Statement [7] is
complex: plenty of factors are reported together, with
Table 3 Risk for acquired hearing loss
1. Positive cultural examination for post congenital infections, viral and
bacterical meningitisa included
2. Head trauma, in particularly with skull base’s or temporal bone’s
fractures that require hospitalization
3. Chemotherapy or ototoxic drugs administrationa
4. Educator’s concerning on hearing, verbal perception, language
development or development delays
ain those cases a follow up protocol is needed
Table 4 Pediatrician’s role
1. Supervise the correct execution of the screening
2. Forward in the audiologic center for an audiologic evaluation, the
babies born in other regions or countries, in which the NHS is not
executed
3. Supervise the refer children, till the execution of the II level test
4. Supervise on babies with risk’s factors for late-onset or progressive
hearing loss, including those with refer TEOAE and pass ABR
5. Supervise on babies with risk’s factors for acquired hearing loss
6. Verify cases that CMV research in urine by PCR had been executed
in all the refer cases
7. Audiological surveillance with BOEL test and submission of health’s
balance questionnaire
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different risk’s indexes (low and high risk). Moreover,
Italian and American health systems are so different that
the classification had got to be necessarily adapted to
the Italian health reality.
For some of the risk’s factors reported in the 2007
JCIH position statement, the real possibility to cause
progressive or late onset hearing loss has not been deter-
mined clearly in scientific literature yet, or it is consid-
ered not-significant or very weak (e.g. congenital
siphilidis or herpes simplex). In fact, the most recent
studies in scientific literature tend to simplify the list of
risk’s factors for progressive or late-onset hearing loss; it
also facilitate the execution of a more selective and ef-
fective follow-up protocol [5, 6, 8].
Moreover, in 2007 JCIH statement, risk’s factors are re-
ported in the same list, those present at birth (e.g. CMV
congenital infection) and those occurred in the perinatal
period which can lead to progressive or late-onset hearing
loss (e.g. prematurity associated conditions). Acquired
conditions, indeed, should be considered independently,
since they require a different surveillance’s protocols.
An audiologic evaluation within the 24 and the
30 months for children with low risk’s condition for pro-
gressive or late-onset hearing loss, as suggested by the
JCIH (2007) may be excessive, difficult and useless, caus-
ing an excessive work loading for the Sanitary System
with a not clear cost/benefit rate. We believe that in
those cases a surveillance by the general paediatrician
could be extremely useful, with the submission of specif-
ically developed questionnaires to parents. Babies identi-
fied in this surveillance protocol and children with
speech delay must be addressed by the paediatrician to
the responsible audiologic centre, for the deepening of
the evaluation with tests appropriated for the age.
Due to these critical issues and after a revision of the
recent literature on the subject, we considered to modify
and simplify the list of risk’s factors, classifying them
into two different distinct tables: risk’s factors for pro-
gressive and late-onset hearing loss (Table 2) and ac-
quired condition that may lead to acquired hearing loss
(Table 3). The enlisted factors are some of those indi-
cated as high-risk’s factors by JCIH in the 2007 Position
Statement. Risk’s factors reported as low-risk by JCIH
has been deleted, since not clearly related with an in-
creased risk of progressive or late-onset hearing loss in
the most recent epidemiological studies [1].
Another issue related to UNHS program is repre-
sented by the possibility to miss some newborns with
light or mild hearing deficits, limited to high frequencies.
In fact, tests used for the I and II level screening
(TOEAE and AABR), even if very reliable, cannot iden-
tify such deficits, for technical limits of the tests.
Another possible cause of missed identification of an
hearing impairment is related with the auditory neuropathy
(AN); in fact a screening executed with the measurement
of TEOAE only is not capable to identify the affected cases.
There are some cases in which newborns have an higher
risk to develop AN. The JCIH statement of 2007 did not
specifically enlist the risk’s factors for AN. In the new Tus-
cany region’s guidelines, such risk’s factors have been identi-
fied, taking inspiration from the audiological risk’s factors
reported in the Position Statement of JCIH, with some
modifications and simplifications (Table 1). Newborns that
present risk’s factors reported in Table 1 has to undergo the
screening with TOAEO and AABR measurement. Anyway,
we should consider that from 20 to 40% of AN cases may
occur in newborns/children without risk’s factor reported
in Table 1, as reported in some recent literature articles [9].
Those cases unavoidably escape from the screening exe-
cuted with TEOAE only, so for the early identification of
cases with AN it is crucial an active audiological surveil-
lance, in which the general paediatrician has a key role in
this.
We believe that for these mentioned reasons a pro-
gram of audiological follow-up and surveillance is cru-
cial. In Italy each child is addressed to a general
paediatrician, so the it plays a key role in the audio-
logical follow-up and surveillance. In Tuscany region’s
screening protocol, the role of the general paediatrician
is underlined and it is suggested that the paediatrician
execute an audiological surveillance during the period-
ical controls with a specifically developed survey, re-
ported in Additional file 1. To this regard, in 2010 all
the general paediatrician of Tuscany region participated
to mandatory training courses in paediatric audiology
and during these courses has been discussed the devel-
opment of a specific audiologic survey. This survey has
been developed then, and it has been included in the
new guidelines and approved by the Regional Sanitary
Council in August 2016. These questionnaires investi-
gate about the hearing and communicative behaviour of
children and about the possible presence of hearing im-
pairments. All the children must undergo the survey, in-
dependently from the result of NHS or from the
presence of risk’s factor for hearing impairment, in order
to identify the cases of acquired or progressive or late-
onset hearing loss, or missed cases at the screening’s
procedures.
Another considerable issue in the audiological new-
born screening protocols and in the early identification
and treatment of infantile hearing impairments is repre-
sented by the congenital CMV infection (cCMV) [10].
Nowadays cCMV infection is considered the first non
genetic cause of infantile deafness and it is an important
reason for many infantile neurodevelopmental disorders;
anyway, since most of newborns with cCMV is symp-
tomless at birth and since a screening protocol for
cCMV does not exist yet, the actual impact and the real
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frequency of this important infection are not yet pre-
cisely defined.
For a certain diagnosis of cCMV a strict temporal
window is available; it is limited at the first 2 or
3 weeks after birth. After this period is difficult to
discriminate from a congenital and an acquired infec-
tion. Those diagnostic issues, together with the lack
of symptoms at birth in most of newborns with
cCMV, are responsible of many cases of misdiagnosed
congenital CMV infection [11]. So, the addition of
CMV testing would help a NHS program to attain an
early audiological diagnosis and to programme an ac-
curate follow-up, as also recently reported by Diener
and colleagues [12].
Further, is it well known that is extremely important to
identify a cCMV as soon as possible. Indeed, many cases
of cCMV related deafness are progressive or late-onset
and so, an early identification of cCMV, makes possible
the execution of an audiological follow up. Further, an
early diagnosis, within the first month from the birth,
make possible to execute, in selected cases, an antiviral
drug treatment in an optimal temporal window [13].
As far as we know, the NHS protocol of the Tuscany
regions is the first to propose and implement a screening
for CMV congenital infection in all the newborns refer
at TEOAE measurement, by the research of CMV gen-
ome by PCR on urine. This procedure permits an early
diagnosis of an eventual cCMV; further it allow to avoid
false positive results and it resolve the diagnostic doubts
on the possibility of a post-natal infection; furthermore
it is important for making possible to set up an audio-
logic follow up in affected babies and for guarantee the
chance to submit the affected babies to the recent thera-
peutic strategies with antiviral drugs.
Williams et al. [14] have recently released a study on
the feasibility of an early diagnostic protocol for cCMV,
and on the acceptability of a screening for cCMV, lim-
ited in babies resulted refer at NHS. The study con-
cluded that the screening for cCMV, executed on saliva
of babies resulted refer at NHS is feasible and well ac-
cepted from the families and, above all, it permits to
identify cases that may benefit from antiviral drugs. Re-
cently our group published a study on the incidence of
cCMV in preterm and small for gestational age (SGA)
babies, hospitalized in Neonatology Operative Unit of
Azienda Ospedaliero Universitaria of Pisa (AOUP) that
have been submitted at screening protocol. An high inci-
dence of cCMV has been found in preterm (3,03%) and
SGA (3,7%) babies. The babies resulted positive for
cCMV resulted also refer at TOAE measurement in the
25% of cases and at ABR meas in 16,7%. According on
this study it seems to exist an important association
between cCMV and prematurity or SGA condition at
birth [11].
Conclusions
The execution of UNHS is the only way to identify new-
borns with congenital moderate to profound hearing
loss. Progressive or late onset hearing loss represents a
relatively large proportion of childhood hearing impair-
ments and may be not identified by the screening, as
well as acquired hearing loss, light-mild hearing loss or
impairments limited to the high frequencies and hearing
loss related to AN or neural deafness. To early identify
those cases an audiological follow-up program is neces-
sary, as well as an audiological surveillance protocol.
The new NHS protocol in Tuscany region considered
all the mentioned issues, as well as it underscores the
role of the general paediatrician in supervising the
screening execution and the audiological evaluation, and
the audiological follow-up and surveillance.
Finally, in consideration of the importance of cCMV as
a cause of hearing loss in childhood, in Tuscany region
all the newborns resulted refer at TEOAE measurement
are early investigated for CMV congenital infection by
the research of CMV DNA in urine by PCR. In Table 5
the main features of the protocol are summarised.
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Abbreviations
AABR: Automatic auditory brainstem responses; ABR: Clinical auditory
brainstem responses; AN: Auditory neuropathy; AOUP: Azienda ospedaliero
universitaria of Pisa (universital ospital of Pisa); cCMV: Congenital
citomegalovirus infection; CI: Cochlear implant; CMV: Citomegalovirus;
DPOAE: Distortion Produced Oto-Acoustic Emissions; ENT: Ear, nose and
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Table 5 Tuscany region’s screening protocol key points
1. Identification of risk factors for AN and execution of TEOAE
and ABR measurements in children with risk’s factors
2. Identification of risk factors for progressive or late onset hearing
loss. Audiological assessment in a III level centre, once every
6–12 months since
the 3rd year of age and then once every year since the 6th
year of age, in children with risk for progressive or late-onset
hearing loss
3. Identification of risk factors for acquired hearing loss
4. Key role of the paediatrician in the supervision on the execution of
screening’s procedure, in the audiologic follow-up, in the
surveillance of children at risk of progressive or late-onset hearing
loss and in the identification of children with risk’s factors for
acquired hearing impairment
5. Screening for CMV congenital infection in all the children resulted
refer at TEOAE measurement, by the research of CMV genome by
PCR on urine,
within the 15th day after birth
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